New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.
| Cat.No. | Product Name | Activity |
| 6264 | Caerulein | CCK agonist |
| 6221 | PKI (5-24) | High affinity PKA inhibitor |
| 6105 | TC AC 28 | High affinity BET bromodomain ligand |
| 5865 | KLH 45 | Potent DDHD2 inhibitor |
| 5437 | Cyanine 7, SE | Near-infrared fluorescent dye for labeling of amines |
| 5435 | Cyanine 3, SE | Orange fluorescent dye for labeling of amines |
| 6250 | Filipin III | Polyene antibiotic; inhibits formation of pathological isoform of prion protein |
| 6233 | Retigabine | KV7 channel activator |
| 6171 | MLS 1547 | G protein-biased D2 receptor partial agonist |
| 6092 | TDZD 8 | Selective non-ATP competitive inhibitor of GSK 3β |
| 6232 | Bosentan | High affinity dual ETA and ETB receptor antagonist;orally bioavailable |
| 6210 | ci-IP3/PM | Caged inositol triphosphate |
| 6204 | 7-Ethoxyresorufin | Fluorometric CYP450 substrate |
| 6146 | LAP | Photocrosslinker for hydrogels |
| 6107 | CP 424174 | Inhibitor of IL-1β post-translational processing; indirectly inhibits NLRP3 |
| 6086 | AMP PNP | Kir6 blocker; non-hydrolyzable AMP analog |
| 6047 | BOP | Dual α9β/1α4β1 integrin inhibitor; preferentially mobilizes HSCs |
| 5932 | Tocriscreen Library of FDA-Approved Compounds | A library of 160 FDA-approved compounds (250 μL 10 mM DMSO solutions) |
| 5758 | AGN 193109 | High affinity pan-RAR antagonist |
| 5820 | AR-C 69931 tetrasodium salt | Highly potent P2Y12 antagonist |
| 5407 | GA3-AM | Gibberellin-analog (GA3) chemical dimerizer; cell permeable |
| 6138 | SR 9243 | Selective LXR inverse agonist |
| 5872 | AZ 10397767 | Potent CXCR2 antagonist |
| 5300 | BI 605906 | Selective IKKβ inhibitor |